Pfizer Presents Interim Analysis Results From Phase 3 BEACON CRC Trial of BRAFTOVI, MEKTOVI and Cetuximab
September 30, 2019
September 30, 2019
NEW YORK, Sept. 30 -- Pfizer, a pharmaceutical company, issued the following news release:
Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI(R) (encorafenib), MEKTOVI(R) (binimetinib), and cetuximab (BRAFTOVI Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy. The results show significant improvements in . . .
Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI(R) (encorafenib), MEKTOVI(R) (binimetinib), and cetuximab (BRAFTOVI Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy. The results show significant improvements in . . .